Welcome to BlogNotions' Life Sciences Blog

The BlogNotions Life Sciences Blog delivers a diverse series of perspectives provided by thought leaders in the life sciences industries. Presented by NetLine, this forum delivers compelling updates on the latest technological advances, discussions of research and findings, best practices for advancing education, implications for the future of various life sciences fields, and much more. Here you can find helpful information, ask questions, and collaborate freely.

When should you outsource drug development

For pharmaceutical companies in flux, contract services are playing a pivotal and more diverse role in the drug development process. The rapid growth of the contract research organization or CRO… The post When should you outsource drug development appeared first on DrugPatentWatch. The post When should you outsource drug development appeared first on Biotechblog.

Continue Reading

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. This ingredient… The post New tentative approval for Watson Labs drug dienogest; estradiol valerate appeared first on DrugPatentWatch. The post New tentative approval for Watson Labs drug […]

Continue Reading

New patent expiration for Pf Prism drug BOSULIF

Annual Drug Patent Expirations for BOSULIF Bosulif is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are five… The post New patent expiration for Pf Prism drug BOSULIF appeared first on DrugPatentWatch. The post New patent expiration for Pf Prism drug BOSULIF appeared […]

Continue Reading

Which pharmaceutical drugs have the most drug patents in Austria?

This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Austria? appeared first on DrugPatentWatch. The post Which pharmaceutical drugs have the most drug […]

Continue Reading

Is importing drugs a risky affair?

The FDA was established to ensure the safety of food and medicines sold in the US. Sadly, the original charter is now slowly being affected by the advocates of drug… The post Is importing drugs a risky affair? appeared first on DrugPatentWatch. The post Is importing drugs a risky affair? appeared first on Biotechblog.

Continue Reading

New patent for Novartis drug TASIGNA

Annual Drug Patent Expirations for TASIGNA Tasigna is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seven patents protecting… The post New patent for Novartis drug TASIGNA appeared first on DrugPatentWatch. The post New patent for Novartis drug TASIGNA appeared first on Biotechblog.

Continue Reading

New patent for Kempharm drug APADAZ

Annual Drug Patent Expirations for APADAZ Apadaz is a drug marketed by Kempharm and is included in one NDA. The generic ingredient in APADAZ is acetaminophen; benzhydrocodone hydrochloride. Additional details… The post New patent for Kempharm drug APADAZ appeared first on DrugPatentWatch. The post New patent for Kempharm drug APADAZ appeared first on Biotechblog.

Continue Reading

Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain

In continuation of my update on lidocaine Sorrento Therapeutics, Inc. , received approval from the U.S. Food and Drug Administration (FDA) for ZTlido (lidocaine topical system) 1.8%. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain. ZTlido is a major advancement in analgesics because of its […]

Continue Reading

Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer

In continuation of my update on Abemaciclib Eli Lilly and Company  announced the U.S. Food and Drug Administration (FDA) has approval of  Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. […]

Continue Reading

FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

In continuation of my update on Apadaz KemPharm, Inc.     announced  the   FDA  approval of  its New Drug Application (NDA) for Apadaz for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Apadaz is an immediate release (IR) combination of KemPharm’s […]

Continue Reading